Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
ACS Med Chem Lett ; 10(1): 132-136, 2019 Jan 10.
Article in English | MEDLINE | ID: mdl-30655960

ABSTRACT

Using a multiplexed, reporter gene-based, high-throughput screen, we identified 9-fluoro-7-hydroxy-3-methyl-5-oxo-N-(pyridin-3-ylmethyl)-2,3-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-6-carboxamide as a TLR2 agonist. Preliminary structure-activity relationship studies on the carboxamide moiety led to the identification of analogues that induce chemokines and cytokines in a TLR2-dependent manner. These results represent new leads for the development of vaccine adjuvants.

2.
Bioconjug Chem ; 29(8): 2741-2754, 2018 08 15.
Article in English | MEDLINE | ID: mdl-29969553

ABSTRACT

Immunogens carried in lymphatic fluid drain via afferent vessels into regional lymph nodes and facilitate the efficient induction of appropriate immune responses. The lymphatic system possesses receptors recognizing hyaluronic acid (HA). Covalent conjugates of small-molecule TLR7/8 agonists with HA are entirely devoid of immunostimulatory activity in vitro. In murine models of immunization, however, such conjugates traffic to lymph nodes, where they are "unmasked", releasing the small molecule TLR7/8 agonist from the carrier polysaccharide. The resulting focal immunostimulation is manifested in potent adjuvantic effects with negligible systemic exposure. The efficient delivery of immunogens has been a major challenge in the development of subunit vaccines, and enhancing targeted delivery of immunogens to secondary lymphoid organs might be a promising approach for improving vaccine efficacy, as well as safety.


Subject(s)
Adjuvants, Immunologic/pharmacology , Hyaluronic Acid/chemistry , Immunoconjugates/pharmacology , Lymph Nodes/drug effects , Membrane Glycoproteins/agonists , Toll-Like Receptor 7/agonists , Toll-Like Receptor 8/agonists , Adjuvants, Immunologic/administration & dosage , Animals , Cytokines/biosynthesis , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Humans , Immunoconjugates/metabolism , Inflammation Mediators/metabolism , Mice , Proof of Concept Study , Vaccines/administration & dosage
3.
J Med Chem ; 60(5): 2084-2098, 2017 03 09.
Article in English | MEDLINE | ID: mdl-28146629

ABSTRACT

The induction of toll-like receptor 7 (TLR7)-dependent type I interferons (IFN-α/ß) from plasmacytoid dendritic cells as well as the production of TLR8-dependent type II interferon (IFN-γ), TNF-α, and IL-12 in myeloid dendritic cells are of importance in generating T helper-1 biased adaptive immune responses. In an effort to identify novel dual TLR7/TLR8-active compounds, we undertook structure-activity relationship studies in pyrimidine 2,4-diamines, focusing on substituents at C5. Several analogues substituted with aminopropyl appendages at C5 displayed dominant TLR8-agonistic activity. N4-Butyl-6-methyl-5-(3-morpholinopropyl)pyrimidine-2,4-diamine was found to be a very potent dual TLR7/TLR8 agonist. Employing novel cytokine reporter cell assays, we verified that potency at TLR7 correlates with IFN-α/ß production in human blood, whereas IFN-γ and TNF-α induction is largely TLR8-dependent. Dual TLR7/TLR8 agonists markedly upregulate CD80 expression in multiple dendritic cell subsets, providing insight into the immunological basis for the superior adjuvantic properties of such innate immune stimuli.


Subject(s)
Diamines/pharmacology , Pyrimidines/pharmacology , Toll-Like Receptor 7/agonists , Toll-Like Receptor 8/agonists , Diamines/chemistry , Humans , Pyrimidines/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL